home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Starve The Tumour, Sabotage The Blood Supply

  January, 4 2007 0:19
your information resource in human molecular genetics
A new drug that shrinks tumours by sabotaging their blood supply may work against cancers that have become resistant to standard anti-angiogenic therapies.

Inhibitors of the molecule Delta-like ligand 4 (Dll4) can shrink tumours in a variety of models, two papers in Nature report. The drug causes an increase in vascularity, but the newly formed blood vessels do not function properly and the tumours become starved of oxygen.

Other anti-angiogenic drugs that target a different protein called vascular endothelial growth factor (VEGF), or its receptor, are already in the clinic but they are not effective against all tumours. Dll4 blockers may work against these anti-VEGF-resistant cancers, say Gavin Thurston and Minhong Yan; they may also work well in combination with anti-VEGF therapies.


Gavin Thurston (Regeneron Pharmaceuticals, Tarrytown, NY, USA)
E-mail: gavin.thurston@regeneron.com

Minhong Yan (Genentech, South San Francisco, CA, USA)
E-mail: minhong@gene.com

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.